Ovarian seromucinous carcinoma
diseaseOn this page
Also known as malignant ovarian mixed epithelial neoplasmmalignant ovarian mixed epithelial tumormalignant ovarian mixed epithelial tumourmixed epithelial carcinoma of the ovarymixed ovarian carcinomaovarian mixed epithelial carcinomaovary mixed epithelial carcinoma
Summary
Ovarian seromucinous carcinoma (MONDO:0004032) is a cancer and 42 clinical trials. Top therapeutic interventions include paclitaxel, topotecan, and gemcitabine. A subtype of ovarian seromucinous tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 42
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ovarian seromucinous carcinoma |
| Mondo ID | MONDO:0004032 |
| DOID | DOID:6898, DOID:6899 |
| NCIT | C40090 |
| UMLS | C0279392 |
| MedGen | 1651770 |
| GARD | 0023786 |
| Is cancer (heuristic) | yes |
Also known as: malignant ovarian mixed epithelial neoplasm · malignant ovarian mixed epithelial tumor · malignant ovarian mixed epithelial tumour · mixed epithelial carcinoma of the ovary · mixed ovarian carcinoma · ovarian mixed epithelial carcinoma · ovarian Seromucinous carcinoma · ovary mixed epithelial carcinoma
Disease family
This is a subtype of ovarian seromucinous tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › ovarian epithelial tumor › ovarian seromucinous tumor › ovarian seromucinous carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 42.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 13 |
| PHASE1 | 11 |
| PHASE3 | 8 |
| Not specified | 4 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
| EARLY_PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00565851 | PHASE3 | ACTIVE_NOT_RECRUITING | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT01167712 | PHASE3 | ACTIVE_NOT_RECRUITING | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT02446600 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT02502266 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer |
| NCT02839707 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT00108745 | PHASE3 | UNKNOWN | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT00262847 | PHASE3 | COMPLETED | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT00719303 | PHASE3 | UNKNOWN | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT00951496 | PHASE3 | COMPLETED | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT01492920 | PHASE3 | WITHDRAWN | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy |
| NCT02068794 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
| NCT02101775 | PHASE2 | ACTIVE_NOT_RECRUITING | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT04739800 | PHASE2 | ACTIVE_NOT_RECRUITING | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents |
| NCT00004221 | PHASE2 | TERMINATED | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer |
| NCT00466960 | PHASE2 | COMPLETED | Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy |
| NCT00888615 | PHASE2 | COMPLETED | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT00939809 | PHASE2 | COMPLETED | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT00993616 | PHASE2 | COMPLETED | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin |
| NCT01010126 | PHASE2 | COMPLETED | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer |
| NCT01097746 | PHASE2 | COMPLETED | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
| NCT02122185 | PHASE2 | COMPLETED | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT02283658 | PHASE2 | COMPLETED | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
| NCT02364713 | PHASE2 | TERMINATED | MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer |
| NCT02923739 | PHASE2 | TERMINATED | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT06393751 | PHASE1/PHASE2 | WITHDRAWN | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer |
| NCT04092270 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer |
| NCT00002913 | PHASE1 | COMPLETED | Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer |
| NCT00060359 | PHASE1 | COMPLETED | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer |
| NCT00079430 | PHASE1 | COMPLETED | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT00085358 | PHASE1 | COMPLETED | Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) |
| NCT00357448 | PHASE1 | COMPLETED | Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer |
| NCT00814086 | PHASE1 | COMPLETED | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer |
| NCT01074411 | PHASE1 | COMPLETED | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT01294293 | PHASE1 | COMPLETED | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer |
| NCT01459380 | PHASE1 | COMPLETED | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT01489371 | PHASE1 | COMPLETED | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT01504126 | EARLY_PHASE1 | COMPLETED | Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT02111941 | EARLY_PHASE1 | COMPLETED | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
| NCT00899093 | Not specified | TERMINATED | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy |
| NCT01080521 | Not specified | COMPLETED | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PACLITAXEL | 4 | 19 |
| TOPOTECAN | 4 | 5 |
| GEMCITABINE | 4 | 2 |
| OLAPARIB | 4 | 2 |
| ATEZOLIZUMAB | 4 | 1 |
| BELINOSTAT | 4 | 1 |
| BEVACIZUMAB | 4 | 1 |
| DENILEUKIN DIFTITOX | 4 | 1 |
| GRANISETRON | 4 | 1 |
| METFORMIN | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| CEDIRANIB | 3 | 5 |
| PACLITAXEL POLIGLUMEX | 3 | 2 |
| VELIPARIB | 3 | 2 |
| ACETYLCARNITINE | 3 | 1 |
| ELESCLOMOL | 3 | 1 |
| EMACTUZUMAB | 3 | 1 |
| ADAVOSERTIB | 2 | 1 |
| ASTX-660 | 1 | 1 |
| NEDISERTIB | 1 | 1 |
| CHEMBL5412235 | 0 | 1 |
| CHEMBL399538 | 0 | 1 |
| S-ROLIPRAM | 0 | 1 |